1) Strategic Overview and Leadership Insights - Gilead's CEO, Daniel O'Day, highlighted the company's strong financial performance in Q1 2026, emphasizing a commitment to financial discipline and a robust product pipeline. - The company is focused on enhancing its market position through strategic acquisitions, including Arcellx, Ouro, and Tubulis, which are expected to bolster Gilead's oncology and inflammation portfolios. - Gilead's HIV business is projected to grow significantly, with up to 7 potential new product launches by 2033, reflecting a strong commitment to innovation in HIV treatment and prevention.

2) Financial Performance and Segment Results - Total product sales (excluding Veklury) reached $6.8 billion, an 8% YoY increase; including Veklury, total sales were $6.9 billion, up 5% YoY. - The HIV segment saw sales of $5 billion, growing 10% YoY, driven by Biktarvy and a remarkable 87% growth in the U.S. PrEP business. - Trodelvy sales increased by 37% YoY to $402 million, reflecting strong demand in breast cancer treatments. - Livdelzi revenue more than tripled YoY to $133 million, maintaining over 50% market share in the U.S. second-line PBC market.

3) Challenges and Headwinds - Sequentially, total product sales declined by 12%, attributed to typical first-quarter seasonality and inventory adjustments. - The company anticipates a 2% headwind in 2026 due to drug pricing agreements and proposed changes to the Affordable Care Act. - Cell therapy sales decreased by 12% YoY to $407 million, reflecting competitive pressures in the market.

4) Operational Plans and Product Development - Gilead is preparing for several key regulatory decisions, including the potential launch of bictegravir plus lenacapavir (BIC/LEN) in August and anito-cel in December. - The company is also focusing on the integration of recent acquisitions and the development of new therapies, including TUB-040 for ovarian cancer and gamgertamig for autoimmune diseases. - Gilead's pipeline now includes 47 clinical programs, with ongoing updates expected across various therapeutic areas throughout 2026.

5) Guidance and Outlook - Gilead has raised its 2026 revenue guidance by $400 million, now expecting total product sales between $30 billion and $30.4 billion. - The company projects 8% YoY growth in HIV sales, up from a previous estimate of 6%, largely driven by the success of Yeztugo. - The anticipated impact of recent acquisitions on operating expenses is expected to be manageable, with a focus on maintaining strong margins.

Bottom line: Gilead's strong Q1 performance, bolstered by innovative product launches and strategic acquisitions, positions the company well for sustained growth in the coming years, despite facing some regulatory and competitive headwinds. Shareholders can expect continued focus on financial discipline and operational excellence as Gilead navigates its robust pipeline and market opportunities.